Compare Sterling Biotech with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs SANOFI INDIA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH SANOFI INDIA STERLING BIOTECH/
SANOFI INDIA
 
P/E (TTM) x -0.4 35.1 - View Chart
P/BV x 0.0 6.1 0.2% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 STERLING BIOTECH   SANOFI INDIA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
SANOFI INDIA
Dec-18
STERLING BIOTECH/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs116,840 0.2%   
Low Rs34,630 0.1%   
Sales per share (Unadj.) Rs26.81,203.1 2.2%  
Earnings per share (Unadj.) Rs-15.0165.3 -9.1%  
Cash flow per share (Unadj.) Rs-5.5209.9 -2.6%  
Dividends per share (Unadj.) Rs084.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs54.9963.6 5.7%  
Shares outstanding (eoy) m267.8723.03 1,163.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.8 5.4%   
Avg P/E ratio x-0.534.7 -1.3%  
P/CF ratio (eoy) x-1.327.3 -4.7%  
Price / Book Value ratio x0.16.0 2.1%  
Dividend payout %050.8 0.0%   
Avg Mkt Cap Rs m1,862132,078 1.4%   
No. of employees `0001.43.3 41.0%   
Total wages/salary Rs m5474,068 13.4%   
Avg. sales/employee Rs Th5,303.38,393.8 63.2%   
Avg. wages/employee Rs Th403.81,232.4 32.8%   
Avg. net profit/employee Rs Th-2,959.01,153.0 -256.6%   
INCOME DATA
Net Sales Rs m7,18127,708 25.9%  
Other income Rs m43897 4.7%   
Total revenues Rs m7,22328,605 25.3%   
Gross profit Rs m9476,235 15.2%  
Depreciation Rs m2,5431,027 247.6%   
Interest Rs m4,3777 62,530.0%   
Profit before tax Rs m-5,9316,098 -97.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9242,292 -84.0%   
Profit after tax Rs m-4,0073,806 -105.3%  
Gross profit margin %13.222.5 58.6%  
Effective tax rate %32.437.6 86.3%   
Net profit margin %-55.813.7 -406.2%  
BALANCE SHEET DATA
Current assets Rs m14,33515,922 90.0%   
Current liabilities Rs m49,8096,235 798.9%   
Net working cap to sales %-494.035.0 -1,413.1%  
Current ratio x0.32.6 11.3%  
Inventory Days Days40364 633.8%  
Debtors Days Days17121 817.8%  
Net fixed assets Rs m55,4327,539 735.3%   
Share capital Rs m268230 116.5%   
"Free" reserves Rs m13,93521,962 63.5%   
Net worth Rs m14,70122,192 66.2%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98829,839 248.0%  
Interest coverage x-0.4872.1 -0.0%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.9 10.5%   
Return on assets %0.512.8 3.9%  
Return on equity %-27.317.2 -158.9%  
Return on capital %-6.427.5 -23.4%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,8607,587 24.5%   
Fx outflow Rs m257,145 0.3%   
Net fx Rs m1,835442 415.1%   
CASH FLOW
From Operations Rs m1,7193,739 46.0%  
From Investments Rs m-3,148-731 430.7%  
From Financial Activity Rs m1,426-1,972 -72.3%  
Net Cashflow Rs m-31,036 -0.3%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.0 14.4 -  
FIIs % 9.9 14.6 67.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 10.5 374.3%  
Shareholders   21,482 15,184 141.5%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  NATCO PHARMA  AUROBINDO PHARMA  PFIZER  

Compare STERLING BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS